Who are [18F]Florbetaben's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Leqembi, Aduhelm, Neuraceq, Vizamyl, Amyvid, M.V.I. Pediatric.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/18f-florbetaben.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

[18F]Florbetaben — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

[18F]Florbetaben ([18F]Florbetaben) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Neurology.

phase 3 Amyloid beta Neurology Small molecule Live · refreshed every 30 min

Target snapshot

[18F]Florbetaben ([18F]Florbetaben) — Ulsan University Hospital. A radioligand used for the imaging of amyloid plaques in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
[18F]Florbetaben TARGET	[18F]Florbetaben	Ulsan University Hospital	phase 3		Amyloid beta
Leqembi	LECANEMAB	Eisai	marketed	Amyloid Beta-directed Antibody [EPC]	Amyloid beta A4 protein	2023-01-01
Aduhelm	ADUCANUMAB	Biogen	marketed	Amyloid Beta-directed Antibody	Amyloid beta A4 protein	2021-01-01
Neuraceq	FLORBETABEN F18	Piramal Imaging	marketed	Radioactive Diagnostic Agent [EPC]	Amyloid beta A4 protein	2014-01-01
Vizamyl	Flutemetamol (18F)	GE HealthCare	marketed	Radioactive Diagnostic Agent [EPC]	Amyloid beta A4 protein	2013-01-01
Amyvid	FLORBETAPIR F 18	Avid Radiopharms Inc	marketed	Radioactive Diagnostic Agent [EPC]	Amyloid beta A4 protein	2012-01-01
M.V.I. Pediatric	RETINOL	Pfizer	marketed	Vitamin A	Amyloid beta A4 protein	1953-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-04-30 — Amyvid · 8506929 · US
2027-04-30 — Amyvid · 7687052 · US
2028-09-16 — Vizamyl · 8916131 · US
2029-03-18 — Neuraceq · 7807135 · US

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). [18F]Florbetaben — Competitive Intelligence Brief. https://druglandscape.com/ci/18f-florbetaben. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab